Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

dc.contributor.author

Ramamurthy, Kavya

dc.contributor.author

Randazzo, Dina M

dc.contributor.author

Cort, Nicole

dc.contributor.author

Herndon, James E

dc.contributor.author

Buckley, Evan

dc.contributor.author

Affronti, Mary Lou

dc.contributor.author

Kim, Jung-Young

dc.contributor.author

Patel, Mallika P

dc.contributor.author

Low, Justin T

dc.contributor.author

Johnson, Margaret O

dc.contributor.author

Khasraw, Mustafa

dc.contributor.author

Desjardins, Annick

dc.contributor.author

Ashley, David M

dc.contributor.author

Friedman, Henry S

dc.contributor.author

Peters, Katherine B

dc.date.accessioned

2026-04-02T16:41:24Z

dc.date.available

2026-04-02T16:41:24Z

dc.date.issued

2025-11

dc.description.abstract

Purpose

With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strategy to alleviate cancer symptoms and improve QoL. Given the potential of this intervention, we hypothesized that mindfulness meditation is feasible and may benefit patients with brain tumors on active therapy by decreasing stress and anxiety.

Methods

Patients with newly diagnosed WHO grade 3-4 malignant glioma were enrolled to evaluate the feasibility of a mindfulness intervention that coincided with standard of care chemoradiation. The intervention consisted of six weekly one-hour telephone-based mindfulness sessions followed by one in-person mindfulness session. QoL was measured by standardized patient-reported outcome questionnaires pre- and post-intervention. Feasibility was assessed within three domains: acceptability, demand, and implementation.

Results

Over a four-month period, 27 patients were offered the opportunity to participate in this study, of which 15 participated. Median age at enrollment was 60 years (range 28-76 years), with enrollees being predominantly female (73.3%) and white (100%). The average percentage of sessions that the patient attended was 82.86% (SD = 28.16). Of the 10 patients who completed the exit interview, 70% indicated they would continue practicing mindfulness. For patients that attend all seven sessions, >50% of patients found the sessions beneficial.

Conclusions

Mindfulness intervention during active treatment for patients with high grade glioma is feasible. Given these results, a larger study has the potential to benefit patients with high grade glioma on active treatment.
dc.identifier

10.1007/s11060-025-05325-1

dc.identifier.issn

0167-594X

dc.identifier.issn

1573-7373

dc.identifier.uri

https://hdl.handle.net/10161/34355

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Journal of neuro-oncology

dc.relation.isversionof

10.1007/s11060-025-05325-1

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Humans

dc.subject

Glioma

dc.subject

Brain Neoplasms

dc.subject

Meditation

dc.subject

Feasibility Studies

dc.subject

Quality of Life

dc.subject

Adult

dc.subject

Aged

dc.subject

Middle Aged

dc.subject

Female

dc.subject

Male

dc.subject

Neoplasm Grading

dc.subject

Mindfulness

dc.title

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

dc.type

Journal article

duke.contributor.orcid

Johnson, Margaret O|0000-0003-1208-622X|0009-0005-5596-3407

duke.contributor.orcid

Khasraw, Mustafa|0000-0003-3249-9849

duke.contributor.orcid

Friedman, Henry S|0000-0001-7588-032X

pubs.begin-page

71

pubs.issue

1

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

School of Nursing

pubs.organisational-group

Nursing

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Biostatistics & Bioinformatics

pubs.organisational-group

Integrative Immunobiology

pubs.organisational-group

Pharmacology & Cancer Biology

pubs.organisational-group

Medicine

pubs.organisational-group

Pathology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Neurology

pubs.organisational-group

Neurology, General & Community Neurology

pubs.organisational-group

Neurosurgery

pubs.organisational-group

Neurosurgery, Neuro-Oncology

pubs.organisational-group

Biostatistics & Bioinformatics, Division of Biostatistics

pubs.organisational-group

Neurosurgery

pubs.publication-status

Published

pubs.volume

176

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ramamurthy K_J NeuroOncol 2025 nov 5_176_1_71.pdf
Size:
871.35 KB
Format:
Adobe Portable Document Format